newsfilter
← Earnings
Earnings Releases·

Compass Therapeutics — Q3 2026 Earnings Summary

  • Reported a net loss of $27.2 million ($0.15/share) for Q3 2026, widening from $14.3 million ($0.08/share) in Q3 2025, driven by a 72% increase in R&D expenses to $22.0 million and a 126% rise in G&A to $6.8 million.
  • The Phase 2/3 COMPANION-002 study for tovecimig met primary endpoints with a statistically significant 18.0% vs. 5.3% improvement in Objective Response Rate and a 56% reduction in progression risk, though the FDA has recommended an additional survival study prior to BLA submission.
  • Cash and marketable securities decreased to $163 million as of September 30, 2026, from $209 million at year-end 2025, with management projecting a cash runway extending into 2028.
  • Strategic outlook includes plans to advance BLA preparations for tovecimig in biliary tract cancer, with expected updates on CTX-8371 and CTX-10726 later in 2026 and initial CTX-471 Phase 2 data anticipated in the second half of 2027.
Company
COMPASS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology